why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat
300×250 Ad Slot

Drug FDA Status

Showing 110 of 139 result(s) (Page 11 of 14)
Drug Name: Pombiliti

Active Ingredient: cipaglucosidase alfa-atga

Approval Date: 2023-09-28

Description:

To treat late-onset Pompe disease
Drug Trials Snapshot

Drug Name: Exxua

Active Ingredient: gepirone

Approval Date: 2023-09-22

Description: To treat major depressive disorder

Drug Name: Ojjaara

Active Ingredient: momelotinib

Approval Date: 2023-09-15

Description: To treat intermediate or high-risk myelofibrosis in adults with anemia

Drug Name: Aphexda

Active Ingredient: motixafortide

Approval Date: 2023-09-08

Description: To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma
Drug Trials Snapshot

Drug Name: Veopoz

Active Ingredient: pozelimab-bbfg

Approval Date: 2023-08-18

Description: To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease

Drug Name: Sohonos

Active Ingredient: palovarotene

Approval Date: 2023-08-16

Description: To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva

Drug Name: Elrexfio

Active Ingredient: elranatamab-bcmm

Approval Date: 2023-08-14

Description: To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy

Drug Name: Talvey

Active Ingredient: talquetamab-tgvs

Approval Date: 2023-08-09

Description: To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies

Drug Name: Izervay

Active Ingredient: avacincaptad pegol

Approval Date: 2023-08-04

Description: To treat geographic atrophy secondary to age-related macular degeneration

Drug Name: Zurzuvae

Active Ingredient: zuranolone

Approval Date: 2023-08-04

Description: To treat postpartum depression 
Press Release

300×250 Ad Slot